CDK2 Inhibitors May Enhance Immunotherapy Across Multiple Cancer Types, Dana-Farber Research Suggests
Source Summary
Researchers at Dana-Farber Cancer Institute have found that cyclin-dependent kinase 2 (CDK2) inhibitors, currently being tested to slow growth in a limited range of cancers, could have broader applications when combined with immunotherapy. The research suggests these inhibitors may enhance immunotherapy response across a wide range of cancer types.
Why it matters
If validated, this finding could expand the therapeutic potential of CDK2 inhibitors beyond their current narrow application to treat multiple cancer types more effectively in combination with immunotherapy.
What remains uncertain
The research is preliminary and suggests potential applications; clinical validation through further testing would be required to confirm efficacy across cancer types.
